Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

por Yi, J H, Lee, J, Lee, J, Park, S H, Park, J O, Yim, D-S, Park, Y S, Lim, H Y, Kang, W K
Publicado 2012

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

por Kim, J. E., Kim, K.K., Kim, S. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Kim, S. T.
Publicado 2017

POS-962 A SURVEY OF COVID-19 INFECTION AMONG VACCINATED AND UNVACCINATED PATIENTS ON RENAL REPLACEMENT THERAPY: A SINGLE CENTRE EXPERIENCE

por Lim, H.Y., Choi, P.L., Makanthran, K., Othman, M.H., Zulkapeli, A.S., SUKESH, H., Ahmad, N.I., Arul Arumugam, P., Goh, B.L.
Publicado 2022

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

por Hong, Y S, Lee, H R, Park, S, Lee, S C, Hwang, I G, Park, B-B, Lee, J, Ahn, J S, Ahn, M-J, Lim, H Y, Park, K
Publicado 2006

Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvan...

por Choi, J-H, Lim, H-Y, Joo, H J, Kim, H S, Yi, J W, Kim, H C, Cho, Y K, Kim, M W, Lee, K B
Publicado 2002

Comparison of p53 gene mutations in paired primary and metastatic gastric tumor tissues.

por Kim, J. H., Choi, J. J., Noh, S. H., Roh, J. K., Min, J. S., Youn, J. K., Yoo, N. C., Lim, H. Y., Carbone, D. P., Gazdar, A. F.
Publicado 1993

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

por Ahn, H K, Choi, J Y, Kim, K-M, Kim, H, Choi, S-H, Park, S H, Park, J O, Lim, H Y, Kang, W K, Lee, J, Park, Y S
Publicado 2013

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection

por Choi, J-H, Lim, H-Y, Nam, D K, Kim, H S, Cho, D Y, Yi, J W, Kim, H C, Cho, Y K, Kim, M W, Joo, H J, Lee, K B, Kim, K B
Publicado 2001

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

por Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Publicado 2014

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

por Lim, S H, Kim, T W, Hong, Y S, Han, S-W, Lee, K-H, Kang, H J, Hwang, I G, Lee, J Y, Kim, H S, Kim, S T, Lee, J, Park, J O, Park, S H, Park, Y S, Lim, H Y, Jung, S-H, Kang, W K
Publicado 2015

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

por Kim, S T, Banks, K C, Pectasides, E, Kim, S Y, Kim, K, Lanman, R B, Talasaz, A, An, J, Choi, M G, Lee, J H, Sohn, T S, Bae, J M, Kim, S, Park, S H, Park, J O, Park, Y S, Lim, H Y, Kim, N K D, Park, W, Lee, H, Bass, A J, Kim, K, Kang, W K, Lee, J
Publicado 2018